Last edition
News about "protein misfolding diseases"
Octant's OCT-980 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
Octant is evaluating OCT-980 in a Phase 1b/2 study at US sites, with the aim of developing a potential oral, disease-modifying treatment for RHO-adRP.
Protein Misfolding Diseases | 29/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members